



MC-2261

PATIENT NAME : VIJETA JAISWAL	REF. DOCTOR : S	SELF
ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703. LADO SARAI, MEHRAULISOUTH WEST	PATIENT ID : VIJEF05058328A	AGE/SEX :40 Years Female DRAWN : RECEIVED :13/05/2023 08:55:34
DELHI NEW DELHI 110030 8800465156	i	REPORTED :13/03/2023 08:33:34 REPORTED :18/05/2023 13:44:08

Results

Test Report Status Preliminary

Biological Reference Interval Units

HAEMATOLOGY - CBC			
MEDI WHEEL FULL BODY HEALTH CHECKUP BE	LOW 40FEMALE		
BLOOD COUNTS, EDTA WHOLE BLOOD			
HEMOGLOBIN (HB) METHOD : SPECTROPHOTOMETRY	11.2 Low	12.0 - 15.0	g/dL
RED BLOOD CELL (RBC) COUNT METHOD : ELECTRICAL IMPEDANCE	4.23	3.8 - 4.8	mil/µL
WHITE BLOOD CELL (WBC) COUNT METHOD : ELECTRICAL IMPEDANCE	7.70	4.0 - 10.0	thou/µL
PLATELET COUNT METHOD : ELECTRICAL IMPEDANCE	130 Low	150 - 410	thou/µL
RBC AND PLATELET INDICES			
HEMATOCRIT (PCV)	34.9 Low	36.0 - 46.0	%
METHOD : CALCULATED PARAMETER MEAN CORPUSCULAR VOLUME (MCV) METHOD : DERIVED/COULTER PRINCIPLE	82.5 Low	83.0 - 101.0	fL
MEAN CORPUSCULAR HEMOGLOBIN (MCH) METHOD : CALCULATED PARAMETER	26.4 Low	27.0 - 32.0	pg
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION (MCHC) METHOD : CALCULATED PARAMETER	32.0	31.5 - 34.5	g/dL
RED CELL DISTRIBUTION WIDTH (RDW) METHOD : DERIVED/COULTER PRINCIPLE	15.6 High	11.6 - 14.0	%
MENTZER INDEX METHOD : CALCULATED PARAMETER	19.5		
MEAN PLATELET VOLUME (MPV) METHOD : DERIVED/COULTER PRINCIPLE	15.3 High	6.8 - 10.9	fL
WBC DIFFERENTIAL COUNT			
NEUTROPHILS METHOD : VCS TECHNOLOGY/ MICROSCOPY	57	40 - 80	%
LYMPHOCYTES METHOD : VCS TECHNOLOGY/ MICROSCOPY	30	20 - 40	%

Dr. Shyla Goel, M.B.B.S , DCP Sr.Pathologist

PERFORMED AT : PERFORMED A1 : Agilus Diagnostics Ltd (Formerly SRL Ltd) B-22, Sector-62 Noida, 201301 Uttar Pradesh, India Tel : 0120-2403338, Fax : CIN - U74899PB1995PLC045956 Email : cuctomercare noida@scl in ${\sf Email: customercare.noida@srl.in}$











PATIENT NAME : VIJETA JAISWAL REF. DOCTOR : SELF CODE/NAME & ADDRESS : C000138361 ACCESSION NO : 0028WE000271 AGE/SEX :40 Years Female ACROFEMI HEALTHCARE LTD (MEDIWHEEL) PATIENT ID : VIJEF05058328A DRAWN : F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED : 13/05/2023 08:55:34 DELHI ABHA NO REPORTED :18/05/2023 13:44:08 : NEW DELHI 110030 8800465156

Test Report Status <u>Preliminary</u>	Results Biological Reference Interval Units		Interval Units
MONOCYTES	9	2.0 - 10.0	%
METHOD : VCS TECHNOLOGY/ MICROSCOPY			
EOSINOPHILS	4	1.0 - 6.0	%
METHOD : VCS TECHNOLOGY/ MICROSCOPY			
BASOPHILS	0	0 - 1	%
METHOD : VCS TECHNOLOGY/ MICROSCOPY			
ABSOLUTE NEUTROPHIL COUNT	4.39	2.0 - 7.0	thou/µL
METHOD : CALCULATED PARAMETER			
ABSOLUTE LYMPHOCYTE COUNT	2.30	1.0 - 3.0	thou/µL
METHOD : CALCULATED PARAMETER			
ABSOLUTE MONOCYTE COUNT	0.70	0.2 - 1.0	thou/µL
METHOD : CALCULATED PARAMETER	0.04		
ABSOLUTE EOSINOPHIL COUNT	0.31	0.02 - 0.50	thou/µL
METHOD : CALCULATED PARAMETER			
ABSOLUTE BASOPHIL COUNT	0.00 Low	0.02 - 0.10	thou/µL
METHOD : CALCULATED PARAMETER			
NEUTROPHIL LYMPHOCYTE RATIO (NLR)	2.0		
METHOD : CALCULATED PARAMETER			

1ethod : Calculated Parameter

Interpretation(s) BLOOD COUNTS,EDTA WHOLE BLOOD-The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology.

RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13) from Beta thalassaemia trait (<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for

diagnosing a case of beta thalassaemia trait. WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive

patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tend to show mild disease. (Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients ; A.-P. Yang, et al.; International Immunopharmacology 84 (2020) 106504

This ratio element is a calculated parameter and out of NABL scope.

Dr. Shyla Goel, M.B.B.S , DCP Sr.Pathologist

PERFORMED AT: Agilus Diagnostics Ltd (Formerly SRL Ltd) B-22, Sector-62 Noida, 201301 Uttar Pradesh, India Tel: 0120-2403338, Fax: CIN - U74899PB1995PLC045956 Email : customercare.noida@srl.in











MC-2261

PATIENT NAME : VIJETA JAISWAL	REF. DOCTOR :	SELF
CODE/NAME & ADDRESS :C000138361 ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	ACCESSION NO : 0028WE000271 PATIENT ID : VIJEF05058328A CLIENT PATIENT ID: ABHA NO :	AGE/SEX :40 Years Female DRAWN : RECEIVED :13/05/2023 08:55:34 REPORTED :18/05/2023 13:44:08
Test Report Status <u>Preliminary</u>	Results Biologica	I Reference Interval Units

н	AEMATOLOGY			
MEDI WHEEL FULL BODY HEALTH CHECKUP BELO	W 40FEMALE			
ERYTHROCYTE SEDIMENTATION RATE (ESR),WHOLE BLOOD				
E.S.R	52 High	< 20	mm at 1 hr	
METHOD : MODIFIED WESTERGREN METHOD BY AUTOMATED ANALYSER				

Interpretation(s) ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD-TEST DESCRIPTION :-

Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic; it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammato condition.CRP is superior to ESR because it is more sensitive and reflects a more rapid change

TEST INTERPRETATION

Increase in: Infections, Vasculities, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy, Estrogen medication, Aging

Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias, Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis). In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum.

Decreased in: Polycythermia vera, Sickle cell anemia

LIMITATIONS

False elevated ESR : Increased fibrinogen, Drugs(Vitamin A, Dextran etc), Hypercholesterolemia False Decreased : Poikilocytosis,(SickleCells,spherocytes),Microcytosis, Low fibrinogen, Very high WBC counts, Drugs(Quinine, salicylates)

REFERENCE :

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition; 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin; 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis, 10th edition.

Dr. Shyla Goel, M.B.B.S , DCP Sr.Pathologist

PERFORMED AT: Agilus Diagnostics Ltd (Formerly SRL Ltd) B-22, Sector-62 Noida, 201301 Uttar Pradesh, India Tel: 0120-2403338, Fax: CIN - U74899PB1995PLC045956 Email : customercare.noida@srl.in





Vie<u>w Details</u>







MC-2261

PATIENT NAME : VIJETA JAISWAL	REF. DOCTOR : S	SELF
ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	PATIENT ID : VIJEF05058328A CLIENT PATIENT ID:	AGE/SEX :40 Years Female DRAWN : RECEIVED :13/05/2023 08:55:34 REPORTED :18/05/2023 13:44:08

Test Report Status **Preliminary** Results

Biological Reference Interval Units

IMMUNOHAEMATOLOGY

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE ABO GROUP & RH TYPE, EDTA WHOLE BLOOD

ABO GROUP	TYPE A
METHOD : COLUMN AGGLUTINATION TECHOLOGY	
RH TYPE	POSITIVE
METHOD : COLUMN AGGLUTINATION TECHOLOGY	

Interpretation(s) ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same."

The test is performed by both forward as well as reverse grouping methods.

Dr. Shyla Goel, M.B.B.S , DCP Sr.Pathologist

PERFORMED AT : Agilus Diagnostics Ltd (Formerly SRL Ltd) B-22, Sector-62 Noida, 201301 Uttar Pradesh, India Tel : 0120-2403338, Fax : CIN - U74899PB1995PLC045956 Email : customercare.noida@srl.in





Page 4 Of 23

View Report





PATIENT NAME : VIJETA JAISWAL REF. DOCTOR : SELF CODE/NAME & ADDRESS : C000138361 ACCESSION NO : 0028WE000271 AGE/SEX :40 Years Female ACROFEMI HEALTHCARE LTD (MEDIWHEEL) PATIENT ID : VIJEF05058328A DRAWN : F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED : 13/05/2023 08:55:34 DELHÍ REPORTED :18/05/2023 13:44:08 ABHA NO NEW DELHI 110030 : 8800465156

Test Report Status Preliminary Results

Biological Reference Interval Units

	BIOCHEMISTRY		
MEDI WHEEL FULL BODY HEALTH CHECKUP	BELOW 40FEMALE		
GLUCOSE FASTING, FLUORIDE PLASMA			
FBS (FASTING BLOOD SUGAR) METHOD : HEXOKINASE	97	74 - 106	mg/dL
GLYCOSYLATED HEMOGLOBIN(HBA1C), EDT BLOOD	A WHOLE		
HBA1C	5.1	Non-diabetic Adult < 5.7 Pre-diabetes 5.7 - 6.4 Diabetes diagnosis: > or = Therapeutic goals: < 7.0 Action suggested : > 8.0 (ADA Guideline 2021)	% = 6.5
ESTIMATED AVERAGE GLUCOSE(EAG)	99.7	< 116.0	mg/dL
GLUCOSE, POST-PRANDIAL, PLASMA			
PPBS(POST PRANDIAL BLOOD SUGAR)	93	Non-Diabetes 70 - 140	mg/dL
METHOD : HEXOKINASE			

Dr. Shyla Goel, M.B.B.S , DCP Sr.Pathologist

PERFORMED AT : Agilus Diagnostics Ltd (Formerly SRL Ltd) B-22, Sector-62 Noida, 201301 Uttar Pradesh, India Tel : 0120-2403338, Fax : CIN - U74899PB1995PLC045956 ${\sf Email: customercare.noida@srl.in}$











PATIENT NAME : VIJETA JAISWAL REF. DOCTOR : SELF CODE/NAME & ADDRESS : C000138361 ACCESSION NO : 0028WE000271 AGE/SEX :40 Years Female ACROFEMI HEALTHCARE LTD (MEDIWHEEL) PATIENT ID : VIJEF05058328A DRAWN : F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED : 13/05/2023 08:55:34 DELHI ABHA NO REPORTED :18/05/2023 13:44:08 : NEW DELHI 110030 8800465156

Test Report Status **Preliminary** Results

Biological Reference Interval Units

Comments

Causes of Low Post Prandial Blood Sugar

The causes of low blood sugar that occurs following a meal have been divided traditionally into

(1)Alimentary

(2)Functional and

(3) That in diabetics and those with impaired glucose tolerance

Alimentary Hypoglycemia usually, but not necessarily, occurs in those patients who have had gastrointestinal surgery. Accelerated absorption of a glucose load leads to marked post - prandial hyperglycemia with a corresponding exaggerated insulin release thus resulting in hypoglycemia the ensuing hypoglycemia typically occurs from one and one half to three hours after eating. This pattern of glucose intolerance and a history of gastrointestinal surgery are suggestive of the diagnosis.

Functional Hypoglycemia is quite common in adults; it may be characterized by abnormally low plasma glucose and symptoms of light headedness, shakiness, diaphoresis, weakness, fatigue occurring with the modest withholding of food. Complaints suggestive of this syndrome commonly are seen in those who have emotional problems.

Post Prandial Hypoglycemia in diabetics: Patients who are diabetics or who have impaired glucose tolerance also may experience reactive hypoglycemia. In these patients, hypoglycemia occurs later than in the group with the alimentary disorder, and insulin response is delayed and exaggerated.

LIPID PROFILE, SERUM			
CHOLESTEROL, TOTAL	222 High	< 200 Desirable 200 - 239 Borderline High >/= 240 High	mg/dL
METHOD : CHOLESTEROL OXIDASE, ESTERASE, PEROXIDASE			
TRIGLYCERIDES	154 High	< 150 Normal 150 - 199 Borderline High 200 - 499 High >/= 500 Very High	mg/dL
METHOD : ENZYMATIC, END POINT			
HDL CHOLESTEROL	51	< 40 Low >/=60 High	mg/dL
METHOD : DIRECT MEASURE POLYMER-POLYANION			
CHOLESTEROL LDL	140 High	< 100 Optimal 100 - 129 Near or above optimal 130 - 159 Borderline High 160 - 189 High >/= 190 Very High	mg/dL

Dr. Shyla Goel, M.B.B.S , DCP Sr.Pathologist

PERFORMED AT: Agilus Diagnostics Ltd (Formerly SRL Ltd) B-22, Sector-62 Noida, 201301 Uttar Pradesh, India Tel: 0120-2403338, Fax: CIN - U74899PB1995PLC045956 Email : customercare.noida@srl.in











PATIENT NAME : VIJETA JAISWAL REF. DOCTOR : SELF CODE/NAME & ADDRESS : C000138361 ACCESSION NO : 0028WE000271 AGE/SEX :40 Years Female ACROFEMI HEALTHCARE LTD (MEDIWHEEL) PATIENT ID DRAWN : VIJEF05058328A : F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED : 13/05/2023 08:55:34 DELHI ABHA NO REPORTED :18/05/2023 13:44:08 : NEW DELHI 110030 8800465156 **Test Report Status Preliminary** Results **Biological Reference Interval** Units

· <u></u>		2
NON HDL CHOLESTEROL	171 High	Desirable: Less than 130 mg/dL Above Desirable: 130 - 159 Borderline High: 160 - 189 High: 190 - 219 Very high: > or = 220
METHOD : CALCULATED PARAMETER		
VERY LOW DENSITY LIPOPROTEIN	30.8	Desirable value : mg/dL 10 - 35
CHOL/HDL RATIO	4.4	3.3-4.4 Low Risk 4.5-7.0 Average Risk 7.1-11.0 Moderate Risk > 11.0 High Risk
LDL/HDL RATIO	2.7	0.5 - 3.0 Desirable/Low Risk 3.1 - 6.0 Borderline/Moderate Risk >6.0 High Risk

Interpretation(s)

Serum lipid profile is measured for cardiovascular risk prediction. Lipid Association of India recommends LDL-C as primary target and Non HDL-C as co-primary treatment target. Risk Stratification for ASCVD (Atherosclerotic cardiovascular disease) by Lipid Association of India

Risk Category				
Extreme risk group	A.CAD with > 1 feature of high risk group	A.CAD with > 1 feature of high risk group		
	B. CAD with > 1 feature of Very high risk	group or recurre	nt ACS (within 1 year) despite LDL-C < or =	
	50 mg/dl or polyvascular disease			
Very High Risk	1. Established ASCVD 2. Diabetes with 2		rs or evidence of end organ damage 3.	
	Familial Homozygous Hypercholesterolem	ia		
High Risk	1. Three major ASCVD risk factors. 2. Di	abetes with 1 ma	ajor risk factor or no evidence of end organ	
	damage. 3. CKD stage 3B or 4. 4. LDL >190 mg/dl 5. Extreme of a single risk factor. 6. Coronary			
	Artery Calcium - CAC >300 AU. 7. Lipoprotein a >/= 50mg/dl 8. Non stenotic carotid plaque			
Moderate Risk	2 major ASCVD risk factors			
Low Risk	0-1 major ASCVD risk factors			
Major ASCVD (Atherosclerotic cardiovascular disease) Risk Factors				
1. Age $>$ or $=$ 45 year	s in males and $>$ or $= 55$ years in females	3. Current Cig	garette smoking or tobacco use	
2. Family history of premature ASCVD 4. High blood pressure		pressure		
5. Low HDL				
Newer treatment goals and statin initiation thresholds based on the risk categories proposed by LAI in 2020.				
Risk Group	Treatment Goals		Consider Drug Therapy	

Dr. Shyla Goel, M.B.B.S , DCP Sr.Pathologist

PERFORMED AT : Agilus Diagnostics Ltd (Formerly SRL Ltd) B-22, Sector-62 Noida, 201301 Uttar Pradesh, India Tel: 0120-2403338, Fax: CIN - U74899PB1995PLC045956 Email : customercare.noida@srl.in











MC-2261

PATIENT NAME : VIJETA JAISWAL	REF. DOCTOR : S	SELF
CODE/NAME & ADDRESS : C000138361	ACCESSION NO : 0028WE000271	AGE/SEX : 40 Years Female
	PATIENT ID : VIJEF05058328A	DRAWN :
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	CLIENT PATIENT ID:	RECEIVED :13/05/2023 08:55:34
NEW DELHI 110030	ABHA NO :	REPORTED :18/05/2023 13:44:08
8800465156		
~		<u> </u>

Test Report Status **Preliminary**

Results

Biological Reference Interval Units

	LDL-C (mg/dl)	Non-HDL (mg/dl)	LDL-C (mg/dl)	Non-HDL (mg/dl)
Extreme Risk Group Category A	<50 (Optional goal	< 80 (Optional goal	>OR = 50	>OR = 80
	< OR = 30)	< OR = 60)		
Extreme Risk Group Category B	<or 30<="" =="" td=""><td><or 60<="" =="" td=""><td>> 30</td><td>>60</td></or></td></or>	<or 60<="" =="" td=""><td>> 30</td><td>>60</td></or>	> 30	>60
Very High Risk	<50	<80	>OR= 50	>OR= 80
High Risk	<70	<100	>OR= 70	>OR=100
Moderate Risk	<100	<130	>OR=100	>OR=130
Low Risk	<100	<130	>OR=130*	>OR=160

*After an adequate non-pharmacological intervention for at least 3 months.

References: Management of Dyslipidaemia for the Prevention of Stroke: Clinical Practice Recommendations from the Lipid Association of India. Current Vascular Pharmacology, 2022, 20, 134-155.

LIVER FUNCTION PROFILE, SERUM

LIVER FUNCTION PROFILE, SERUM			
BILIRUBIN, TOTAL METHOD : DIAZONIUM ION, BLANKED (ROCHE)	0.92	UPTO 1.2	mg/dL
BILIRUBIN, DIRECT	0.26	0.00 - 0.30	mg/dL
BILIRUBIN, INDIRECT	0.66 High	0.00 - 0.60	mg/dL
TOTAL PROTEIN METHOD : BIURET,SERUM BLANK,ENDPOINT	7.5	6.6 - 8.7	g/dL
ALBUMIN METHOD : BROMOCRESOL GREEN	4.5	3.97 - 4.94	g/dL
GLOBULIN	3.0	2.0 - 4.0 Neonates - Pre Mature: 0.29 - 1.04	g/dL
METHOD : CALCULATED PARAMETER			
ALBUMIN/GLOBULIN RATIO METHOD : CALCULATED PARAMETER	1.5	1.0 - 2.0	RATIO
ASPARTATE AMINOTRANSFERASE(AST/SGOT) METHOD : UV WITHOUT P5P	18	0 - 32	U/L
ALANINE AMINOTRANSFERASE (ALT/SGPT) METHOD : UV WITHOUT P5P	17	0 - 31	U/L
ALKALINE PHOSPHATASE METHOD : PNPP, AMP BUFFER-IFCC	81	35 - 105	U/L
GAMMA GLUTAMYL TRANSFERASE (GGT)	18	5 - 36	U/L
LACTATE DEHYDROGENASE METHOD : L TO P, IFCC	207	135 - 214	U/L

Dr. Shyla Goel, M.B.B.S , DCP Sr.Pathologist

PERFORMED AT : Agilus Diagnostics Ltd (Formerly SRL Ltd) B-22, Sector-62 D-22, Sector-62 Noida, 201301 Uttar Pradesh, India Tel : 0120-2403338, Fax : CIN - U74899PB1995PLC045956 Email : customercare.noida@srl.in



Page 8 Of 23

View Report







PATIENT NAME : VIJETA JAISWAL REF. DOCTOR : SELF CODE/NAME & ADDRESS : C000138361 ACCESSION NO : 0028WE000271 AGE/SEX :40 Years Female ACROFEMI HEALTHCARE LTD (MEDIWHEEL) PATIENT ID : VIJEF05058328A DRAWN : F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED : 13/05/2023 08:55:34 DELHÍ REPORTED :18/05/2023 13:44:08 ABHA NO NEW DELHI 110030 : 8800465156

 Test Report Status
 Preliminary
 Results
 Biological Reference Interval
 Units

BLOOD UREA NITROGEN (BUN), SERUM BLOOD UREA NITROGEN METHOD : UREASE - UV	15	6 - 20	mg/dL
CREATININE, SERUM CREATININE METHOD : ALKALINE PICRATE-KINETIC	0.66	0.50 - 0.90	mg/dL
BUN/CREAT RATIO BUN/CREAT RATIO METHOD : CALCULATED PARAMETER	22.73 High	5.00 - 15.00	
URIC ACID, SERUM URIC ACID METHOD : URICASE, COLORIMETRIC	4.7	2.4 - 5.7	mg/dL
TOTAL PROTEIN, SERUM TOTAL PROTEIN METHOD : BIURET, SERUM BLANK, ENDPOINT	7.5	6.6 - 8.7	g/dL
ALBUMIN, SERUM ALBUMIN METHOD : BROMOCRESOL GREEN	4.5	3.97 - 4.94	g/dL

Dr. Shyla Goel,M.B.B.S ,DCP Sr.Pathologist

PERFORMED AT : Agilus Diagnostics Ltd (Formerly SRL Ltd) B-22, Sector-62 Noida, 201301 Uttar Pradesh, India Tel : 0120-2403338, Fax : CIN - U74899PB1995PLC045956 Email : customercare.noida@srl.in



•**

Page 9 Of 23

View Report





2.0 - 4.0 Neonates -Pre Mature: 0.29 - 1.04



g/dL

MC-2261

PATIENT NAME : VIJETA JAISWAL	REF. DOCTOF	R: SELF
CODE/NAME & ADDRESS : C000138361 ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	ACCESSION NO : 0028WE000271 PATIENT ID : VIJEF05058328A CLIENT PATIENT ID: ABHA NO :	AGE/SEX :40 Years Female DRAWN : RECEIVED :13/05/2023 08:55:34 REPORTED :18/05/2023 13:44:08
Test Report Status <u>Preliminary</u>	Results Biologi	cal Reference Interval Units
GLOBULIN		

METHOD :	CALCULATED	PARAMETER

GLOBULIN

ELECTROLYTES (NA/K/CL), SERUM			
SODIUM, SERUM	138	136 - 145	mmol/L
METHOD : ISE INDIRECT			
POTASSIUM, SERUM	4.05	3.5 - 5.1	mmol/L
METHOD : ISE INDIRECT			
CHLORIDE, SERUM	102	98 - 107	mmol/L
METHOD : ISE INDIRECT			

3.0

Interpretation(s)

Sodium	Potassium	Chloride
Decreased in:CCF, cirrhosis, vomiting, diarrhea, excessive sweating, salt-losing nephropathy, adrenal insufficiency, nephrotic syndrome, water intoxication, SIADH. Drugs: thiazides, diuretics, ACE inhibitors, chlorpropamide, carbamazepine, anti depressants (SSRI), antipsychotics.	Decreased in: Low potassium intake,prolonged vomiting or diarrhea, RTA types I and II, hyperaldosteronism, Cushing's syndrome,osmotic diuresis (e.g., hyperglycemia),alkalosis, familial periodic paralysis,trauma (transient).Drugs: Adrenergic agents, diuretics.	Decreased in: Vomiting, diarrhea, renal failure combined with salt deprivation, over-treatment with diuretics, chronic respiratory acidosis, diabetic ketoacidosis, excessive sweating, SIADH, salt-losing nephropathy, porphyria, expansion of extracellular fluid volume, adrenalinsufficiency, hyperaldosteronism,metabolic alkalosis. Drugs: chronic laxative,corticosteroids, diuretics.
Increased in: Dehydration (excessivesweating, severe vomiting or diarrhea),diabetes mellitus, diabetesinsipidus, hyperaldosteronism, inadequate water intake. Drugs: steroids, licorice,oral contraceptives.	Increased in: Massive hemolysis, severe tissue damage, rhabdomyolysis, acidosis, dehydration,renal failure, Addison' s disease, RTA type IV, hyperkalemic familial periodic paralysis. Drugs: potassium salts, potassium- sparing diuretics,NSAIDs, beta-blockers, ACE inhibitors, high- dose trimethoprim-sulfamethoxazole.	Increased in: Renal failure, nephrotic syndrome, RTA, dehydration, overtreatment with saline, hyperparathyroidism, diabetes insipidus, metabolic acidosis from diarrhea (Loss of HCO3-), respiratory alkalosis, hyperadrenocorticism. Drugs: acetazolamide, androgens, hydrochlorothiazide, salicylates.

Dr. Shyla Goel, M.B.B.S , DCP Sr.Pathologist

PERFORMED AT : PERFORMED A1 : Agilus Diagnostics Ltd (Formerly SRL Ltd) B-22, Sector-62 Noida, 201301 Uttar Pradesh, India Tel : 0120-2403338, Fax : CIN - U74899PB1995PLC045956 Email : cuctomercare noida@scl in ${\sf Email: customercare.noida@srl.in}$

Page 10 Of 23

1









Biological Reference Interval Units

PATIENT NAME : VIJETA JAISWAL	REF. DOCTOR : S	SELF
		AGE/SEX :40 Years Female
F-703. LADO SARAI. MEHRAULISOUTH WEST	VISE 05050520/(DRAWN : RECEIVED : 13/05/2023 08:55:34
NEW DELHI 110030 8800465156	ABHA NO :	REPORTED :18/05/2023 13:44:08
	<u>i</u>	<u> </u>

Interferences: Severe lipemia or hyperproteinemi, if sodium analysis involves a dilution step can cause spurious results. The serum sodium falls about 1.6 mEq/L for each 100 mg/dL increase in blood glucose.	Interferences: Hemolysis of sample, delayed separation of serum, prolonged fist clenching during blood drawing, and prolonged tourniquet placement. Very high WBC/PLT counts may cause spurious. Plasma potassium levels are normal.	Interferences:Test is helpful in assessing normal and increased anion gap metabolic acidosis and in distinguishing hypercalcemia due to hyperparathyroidism (high serum chloride) from that due to malignancy (Normal serum chloride)

Interpretation(s)

Test Report Status

GLUCOSE FASTING, FLUORIDE PLASMA-TEST DESCRIPTION

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted in the

Increased in:Diabetes mellitus, Cushing's syndrome (10 – 15%), chronic pancreatitis (30%). Drugs:corticosteroids,phenytoin, estrogen, thiazides. Decreased in :Pancreatic islet cell disease with increased insulin,insulinoma,adrenocortical insufficiency,hypopituitarism,diffuse liver disease,

malignancy(adrenocortical,stomach,fibrosarcoma),infant of a diabetic mother,enzyme deficiency

Note: While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within

Results

individuals. Thus, glycosylated hemoglobin(HbA1c) levels are favored to monitor glycemic control. High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed,Alimentary Hypoglycemia,Increased insulin response & sensitivity etc. GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-**Used For**:

1. Evaluating the long-term control of blood glucose concentrations in diabetic patients.

Preliminary

2. Diagnosing diabetes

3. Identifying patients at increased risk for diabetes (prediabetes).

The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patients metabolic control has remained continuously within the target range.

1. eAG (Estimated average glucose) converts percentage HbA1c to md/dl, to compare blood glucose levels.

 eAG gives an evaluation of blood glucose levels for the last couple of months. 3. eAG is calculated as eAG (mg/dl) = 28.7 * HbA1c - 46.7

HbA1c Estimation can get affected due to :

1. Shortened Erythrocyte survival : Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss, hemolytic anemia) will falsely lower HbA1c test results. Fructosamine is recommended in these patients which indicates diabetes control over 15 days.

2.Vitamin C & E are reported to falsely lower test results. (possibly by inhibiting glycation of hemoglobin.

3. Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates addiction are reported to interfere with some assay methods, falsely increasing results.

4. Interference of hemoglobinopathies in HbA1c estimation is seen in

a) Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c.b) Heterozygous state detected (D10 is corrected for HbS & HbC trait.)

c) HbF > 25% on alternate paltform (Boronate affinity chromatography) is recommended for testing of HbA1c. Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin

treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc. Additional test HbA1c LIVER FUNCTION PROFILE, SERUM-

Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give yellow discoloration in jaundice. **Elevated levels** results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin is also elevated more than unconjugated (indirect) bilirubin when there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors &Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver, liver cancer, kidney failure, hemolytic anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attack or strenuous activity. ALT test measures the amount of this enzyme in the blood. ALT is found mainly in the liver, but also in smaller amounts in the kidneys, heart, muscles, and pancreas. It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health.AST levels increase during acute hepatitis, sometimes due to a viral infection, ischemia to the liver, chronic hepatitis, obstruction of bile ducts, cirrhosis.

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction,



Dr. Shyla Goel, M.B.B.S , DCP Sr.Pathologist





Page 11 Of 23







PATIENT NAME : VIJETA JAISWAL	REF. DOCTOR : S	SELF
	ACCESSION NO : 0028WE000271 PATIENT ID : VIJEF05058328A CLIENT PATIENT ID: ABHA NO :	AGE/SEX :40 Years Female DRAWN : RECEIVED :13/05/2023 08:55:34 REPORTED :18/05/2023 13:44:08
Test Report Status <u>Preliminary</u>	Results Biological	Reference Interval Units

Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Pagets disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia, Malnutrition, Protein deficiency, Wilsons disease.

GGT is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, biliary system and pancreas. Conditions that increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc.

Total Protein also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease.Lower-than-normal levels may be due to: Agammaglobulinemia,Bleeding (hemorrhage),Burns,Glomerulonephritis,Liver disease, Malabsorption,Malnutrition,Nephrotic

syndrome, Protein-losing enteropathy etc. Albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels

(hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc

BLODD UREA NITROGEN (BUN), SERUM-Causes of Increased levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism) Causes of decreased level include Liver disease, SIADH.

CREATININE, SERUM-**Higher than normal level may be due to:**Blockage in the urinary tract, Kidney problems, such as kidney damage or failure, infection, or reduced blood flow, Loss of body fluid (dehydration), Muscle problems, such as breakdown of muscle fibers, Problems during pregnancy, such as seizures (eclampsia)), or high blood pressure caused by pregnancy (preeclampsia) Lower than normal level may be due to:• Myasthenia Gravis, Muscuophy

URIC ACID, SERUM-Causes of Increased levels-Dietary(High Protein Intake,Prolonged Fasting,Rapid weight loss),Gout,Lesch nyhan syndrome,Type 2 DM,Metabolic syndrome Causes of decreased levels-Low Zinc intake,OCP,Multiple Sclerosis TOTAL PROTEIN, SERUM-is a biochemical test for measuring the total amount of protein in serum.Protein in the plasma is made up of albumin and globulin.

Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc.

ALBUMIN, SERUM-Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc.

Dr. Shyla Goel, M.B.B.S , DCP Sr.Pathologist

PERFORMED AT: Agilus Diagnostics Ltd (Formerly SRL Ltd) B-22, Sector-62 Noida, 201301 Uttar Pradesh, India Tel: 0120-2403338, Fax: CIN - U74899PB1995PLC045956 Email : customercare.noida@srl.in



Page 12 Of 23







PATIENT NAME : VIJETA JAISWAL REF. DOCTOR : SELF CODE/NAME & ADDRESS : C000138361 ACCESSION NO : 0028WE000271 AGE/SEX :40 Years Female ACROFEMI HEALTHCARE LTD (MEDIWHEEL) PATIENT ID : VIJEF05058328A DRAWN : F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED : 13/05/2023 08:55:34 DELHÍ REPORTED :18/05/2023 13:44:08 ABHA NO : NEW DELHI 110030 8800465156

Test Report Status	Preliminary
--------------------	--------------------

Results

Biological Reference Interval Units

MEDI WHEEL FULL BODY HEALTH CHECKUP B	ELOW 40FEMALE		·
PHYSICAL EXAMINATION, URINE			
COLOR	PALE YELLOW		
	SLIGHTLY HAZY		
METHOD : VISUAL			
CHEMICAL EXAMINATION, URINE			
PH	6.0	4.7 - 7.5	
METHOD : DOUBLE INDICATOR PRINCIPLE SPECIFIC GRAVITY	<=1.005	1.003 - 1.035	
METHOD : PKA CHANGE OF PRETREATED POLYELECTROLYTES			
PROTEIN	NOT DETECTED	NOT DETECTED	
METHOD : PROTEIN- ERROR INDICATOR GLUCOSE	NOT DETECTED	NOT DETECTED	
METHOD : OXIDASE-PEROXIDASE REACTION	NOT DETECTED		
KETONES	NOT DETECTED	NOT DETECTED	
METHOD : ACETOACETIC REACTION WITH NITROPRUSSIDE		NOT DETECTED	
BLOOD METHOD : PEROXIDASE-LIKE ACTIVITY OF HEMOGLOBIN	NOT DETECTED	NOT DETECTED	
BILIRUBIN	NOT DETECTED	NOT DETECTED	
	NORMAL	NORMAL	
UROBILINOGEN METHOD : MODIFIED EHRLICH REACTION	NORMAL	NORMAL	
NITRITE	NOT DETECTED	NOT DETECTED	
METHOD : CONVERTION OF NITRATE TO NITRITE			
	NOT DETECTED	NOT DETECTED	
METHOD : ESTERASE HYDROLYSIS ACTIVITY			

MICROSCOPIC EXAMINATION, URINE

RED BLOOD CELLS	NOT DETECTED	NOT DETECTED	/HPF
METHOD : MICROSCOPIC EXAMINATION PUS CELL (WBC'S)	3-5	0-5	/HPF

Dr. Shyla Goel,M.B.B.S ,DCP Sr.Pathologist

PERFORMED AT : Agilus Diagnostics Ltd (Formerly SRL Ltd) B-22, Sector-62 Noida, 201301 Uttar Pradesh, India Tel : 0120-2403338, Fax : CIN - U74899PB1995PLC045956 Email : customercare.noida@srl.in



View Report

•**

View Details







PATIENT NAME : VIJETA JAISWAL REF. DOCTOR : SELF CODE/NAME & ADDRESS : C000138361 ACCESSION NO : 0028WE000271 AGE/SEX :40 Years Female ACROFEMI HEALTHCARE LTD (MEDIWHEEL) PATIENT ID : VIJEF05058328A DRAWN : F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED : 13/05/2023 08:55:34 DELHI ABHA NO REPORTED :18/05/2023 13:44:08 : NEW DELHI 110030 8800465156 **Test Report Status Preliminary** Results **Biological Reference Interval** Units METHOD : MICROSCOPIC EXAMINATION /HPF EPITHELIAL CELLS 1-2 0-5 METHOD : MICROSCOPIC EXAMINATION CASTS NOT DETECTED METHOD : MICROSCOPIC EXAMINATION NOT DETECTED CRYSTALS METHOD : MICROSCOPIC EXAMINATION **DETECTED** (++) NOT DETECTED BACTERIA METHOD : MICROSCOPIC EXAMINATION

> **DETECTED** (+) NOT DETECTED

MICROSCOPIC EXAMINATION DONE ON CENTRIFUGED URINEPLEASE NOTE THAT GRADING OF BACTERIA NEEDS TO BE CORELATED WITH THE CULTURE IN CASE FOUND SIGNIFICANT CLINICALLY. OCCASIONAL BACTERIA/YEAST CELLS SEEN IN MICROSCOPY CAN BE A PART OF SURROUNDING SKIN FLORA ALSO.

METHOD : MANUAL

YEAST

REMARKS

Interpretation(s)

The following table describes the probable conditions, in which the analytes are present in urine

Presence of	Conditions
Proteins	Inflammation or immune illnesses
Pus (White Blood Cells)	Urinary tract infection, urinary tract or kidney stone, tumors or any kind
	of kidney impairment
Glucose	Diabetes or kidney disease
Ketones	Diabetic ketoacidosis (DKA), starvation or thirst
Urobilinogen	Liver disease such as hepatitis or cirrhosis
Blood	Renal or genital disorders/trauma
Bilirubin	Liver disease
Erythrocytes	Urological diseases (e.g. kidney and bladder cancer, urolithiasis), urinary
	tract infection and glomerular diseases
Leukocytes	Urinary tract infection, glomerulonephritis, interstitial nephritis either
	acute or chronic, polycystic kidney disease, urolithiasis, contamination by
	genital secretions
Epithelial cells	Urolithiasis, bladder carcinoma or hydronephrosis, ureteric stents or
	bladder catheters for prolonged periods of time

Dr. Shyla Goel, M.B.B.S , DCP Sr.Pathologist

PERFORMED AT: Agilus Diagnostics Ltd (Formerly SRL Ltd) B-22, Sector-62 Noida, 201301 Uttar Pradesh, India Tel: 0120-2403338, Fax: CIN - U74899PB1995PLC045956 Email : customercare.noida@srl.in









AGE/SEX

REF. DOCTOR : SELF



Female

PATIENT NAME : VIJETA JAISWAL

CODE/NAME & ADDRESS : C000138361 ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156

ACCESSION NO : **0028WE000271** PATIENT ID : VIJEF05058328A CLIENT PATIENT ID: ABHA NO :

DRAWN : RECEIVED :13/05/2023 08:55:34 REPORTED :18/05/2023 13:44:08

:40 Years

Test Report Status	<u>Preliminary</u>	Results	Biological Reference Interval	Units
--------------------	--------------------	---------	--------------------------------------	-------

Granular Casts	Low intratubular pH, high urine osmolality and sodium concentration, interaction with Bence-Jones protein
Hyaline casts	Physical stress, fever, dehydration, acute congestive heart failure, renal diseases
Calcium oxalate	Metabolic stone disease, primary or secondary hyperoxaluria, intravenous infusion of large doses of vitamin C, the use of vasodilator naftidrofuryl oxalate or the gastrointestinal lipase inhibitor orlistat, ingestion of ethylene glycol or of star fruit (Averrhoa carambola) or its juice
Uric acid	arthritis
Bacteria	Urinary infectionwhen present in significant numbers & with pus cells.
Trichomonas vaginalis	Vaginitis, cervicitis or salpingitis

Dr. Shyla Goel,M.B.B.S ,DCP Sr.Pathologist

PERFORMED AT : Agilus Diagnostics Ltd (Formerly SRL Ltd) B-22, Sector-62 Noida, 201301 Uttar Pradesh, India Tel : 0120-2403338, Fax : CIN - U74899PB1995PLC045956 Email : customercare.noida@srl.in







View Report







PATIENT NAME : VIJETA JAISWAL REF. DOCTOR : SELF CODE/NAME & ADDRESS : C000138361 ACCESSION NO : 0028WE000271 AGE/SEX :40 Years Female ACROFEMI HEALTHCARE LTD (MEDIWHEEL) PATIENT ID : VIJEF05058328A DRAWN : F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED : 13/05/2023 08:55:34 DELHÍ REPORTED :18/05/2023 13:44:08 ABHA NO : NEW DELHI 110030 8800465156

Test Report Status Preliminary

Results

Biological Reference Interval Units

	CYTOLOGY	
MEDI WHEEL FULL BODY HEALTH	CHECKUP BELOWREGUE MADE	
PAPANICOLAOU SMEAR	RESULT PENDING	

Page 16 Of 23



View Report



View Details

PERFORMED AT : Agilus Diagnostics Ltd (Formerly SRL Ltd) B-22, Sector-62 Noida, 201301 Uttar Pradesh, India Tel : 0120-2403338, Fax : CIN - U74899PB1995PLC045956 Email : customercare.noida@srl.in





ng/dL

MC-2261

PATIENT NAME : VIJETA JAISWAL	REF. DOCTOR : S	SELF
CODE/NAME & ADDRESS : C000138361 ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	PATIENT ID : VIJEF05058328A	AGE/SEX :40 Years Female DRAWN : RECEIVED :13/05/2023 08:55:34
NEW DELHI 110030 8800465156	ABHA NO :	REPORTED :18/05/2023 13:44:08

Test Report Status Preliminary

Results

Biological Reference Interval Units

2nd Trimester: 0.35 - 4.10 3rd Trimester: 0.21 - 3.15

SPECIALISED CHEMISTRY - HORMONE

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE **THYROID PANEL, SERUM** Т3 112.6 80.00 - 200.00

T4	8.88	5.10 - 14.10	µg/dL
TSH (ULTRASENSITIVE)	4.740 High	Non Pregnant Women 0.27 - 4.20 Pregnant Women 1st Trimester: 0.33 - 4.59	µIU/mL

Dr. Shyla Goel, M.B.B.S , DCP Sr.Pathologist

PERFORMED AT : Agilus Diagnostics Ltd (Formerly SRL Ltd) B-22, Sector-62 Noida, 201301 Uttar Pradesh, India Tel : 0120-2403338, Fax : CIN - U74899PB1995PLC045956 Email : ustomerare peide @erl in ${\sf Email: customercare.noida@srl.in}$







View Report

Details





PATIENT NAME : VIJETA JAISWAL REF. DOCTOR : SELF CODE/NAME & ADDRESS : C000138361 ACCESSION NO : 0028WE000271 AGE/SEX :40 Years Female ACROFEMI HEALTHCARE LTD (MEDIWHEEL) PATIENT ID : VIJEF05058328A DRAWN : F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED : 13/05/2023 08:55:34 DELHI ABHA NO REPORTED :18/05/2023 13:44:08 : NEW DELHI 110030 8800465156 **Test Report Status Biological Reference Interval** Units

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

Preliminary

XRAY-CHEST

»»	BOTH THE LUNG FIELDS ARE CLEAR
»»	BOTH THE COSTOPHRENIC AND CARIOPHRENIC ANGELS ARE CLEAR
»»	BOTH THE HILA ARE NORMAL
»»	CARDIAC AND AORTIC SHADOWS APPEAR NORMAL
»»	BOTH THE DOMES OF THE DIAPHRAM ARE NORMAL
»»	VISUALIZED BONY THORAX IS NORMAL
IMPRESSION	NORMAL

Results

TMT OR ECHO

TMT OR ECHO

TMT DONE - NORMAL

ECG

ECG

WITHIN NORMAL LIMITS

MEDICAL HISTORY

RELEVANT PRESENT HISTORY	hypothyrodism since 10 years
RELEVANT PAST HISTORY	COVID POSITIVE 2021
RELEVANT PERSONAL HISTORY	MARRIED 1 CHILD NON VEG
MENSTRUAL HISTORY (FOR FEMALES)	REGULAR
LMP (FOR FEMALES)	24/4/2023
RELEVANT FAMILY HISTORY	HIGH BLOOD PRESSURE MOTEHR AND FATHER
OCCUPATIONAL HISTORY	HOUSE WIFE
HISTORY OF MEDICATIONS	NOT SIGNIFICANT

ANTHROPOMETRIC DATA & BMI

Page 18 Of 23



View Report



PERFORMED AT : Agilus Diagnostics Ltd (Formerly SRL Ltd) E-368, Lgf, Nirman Vihar,Near Nirman Vihar Metro New Delhi, 110092 New Delhi, India Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956 Email : wellness.eastdelhi@srl.in



PATIENT NAME : VIJETA JAISWAL	R	EF. DOCTOR :	SELF
CODE/NAME & ADDRESS : C000138361 ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	ACCESSION NO: 0028W PATIENT ID : VIJEF05 CLIENT PATIENT ID: ABHA NO :		AGE/SEX :40 Years Female DRAWN : RECEIVED :13/05/2023 08:55:34 REPORTED :18/05/2023 13:44:08
Test Report Status <u>Preliminary</u>	Results	Biologica	al Reference Interval Units
HEIGHT IN METERS	1.53		mts
WEIGHT IN KGS.	73.7		Kgs
ВМІ	31 BMI & Weight Status as followg/sqmts Below 18.5: Underweight 18.5 - 24.9: Normal 25.0 - 29.9: Overweight 30.0 and Above: Obese		
GENERAL EXAMINATION			
MENTAL / EMOTIONAL STATE	NORMAL		
PHYSICAL ATTITUDE	NORMAL		
GENERAL APPEARANCE / NUTRITIONAL STATUS	HEALTHY		
BUILT / SKELETAL FRAMEWORK	AVERAGE		
FACIAL APPEARANCE	NORMAL		
SKIN	NORMAL		
UPPER LIMB	NORMAL		
LOWER LIMB	NORMAL		
NECK	NORMAL		
NECK LYMPHATICS / SALIVARY GLANDS	NOT ENLARGED OR TEN	DER	
THYROID GLAND	NOT ENLARGED		
CAROTID PULSATION	NORMAL		
TEMPERATURE	NORMAL		
PULSE	CAROTID BRUIT	ALL PERIPHER	AL PULSES WELL FELT, NO
RESPIRATORY RATE	NORMAL		
CARDIOVASCULAR SYSTEM			
BP	110/74		mm/Hg
PERICARDIUM	NORMAL		

NORMAL

NORMAL

Page 19 Of 23



View Details

PERFORMED AT : PERFORMED A1 : Agilus Diagnostics Ltd (Formerly SRL Ltd) E-368, Lgf, Nirman Vihar,Near Nirman Vihar Metro New Delhi, 110092 New Delhi, India Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956 Email : wollpace acatdebi@crf in Email : wellness.eastdelhi@srl.in

APEX BEAT HEART SOUNDS

.

.

View Report Patient Ref. No. 775000003205584



PATIENT NAME : VIJETA JAISWAL	REF. DOCTOR :	SELF
ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	ACCESSION NO: 0028WE000271 PATIENT ID : VIJEF05058328A CLIENT PATIENT ID: ABHA NO :	AGE/SEX :40 Years Female DRAWN : RECEIVED :13/05/2023 08:55:34 REPORTED :18/05/2023 13:44:08
Test Report Status <u>Preliminary</u>	Results Biological	Reference Interval Units

MURMURS

ABSENT

RESPIRATORY SYSTEM

SIZE AND SHAPE OF CHEST	NORMAL
MOVEMENTS OF CHEST	SYMMETRICAL
BREATH SOUNDS INTENSITY	NORMAL
BREATH SOUNDS QUALITY	VESICULAR (NORMAL)
ADDED SOUNDS	ABSENT

PER ABDOMEN

APPEARANCE	NORMAL
VENOUS PROMINENCE	ABSENT
LIVER	NOT PALPABLE
SPLEEN	NOT PALPABLE

CENTRAL NERVOUS SYSTEM

HIGHER FUNCTIONS	NORMAL
CRANIAL NERVES	NORMAL
CEREBELLAR FUNCTIONS	NORMAL
SENSORY SYSTEM	NORMAL
MOTOR SYSTEM	NORMAL
REFLEXES	NORMAL

MUSCULOSKELETAL SYSTEM

SPINE	NORMAL
JOINTS	NORMAL

.

Page 20 Of 23

1

Τ.







PERFORMED AT : Agilus Diagnostics Ltd (Formerly SRL Ltd) E-368, Lgf, Nirman Vihar,Near Nirman Vihar Metro New Delhi, 11:002 New Delhi, India Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956 Email : wellness.eastdelhi@srl.in



PATIENT NAME : VIJETA JAISWAL	REF. DOCTOR :	SELF
ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	ACCESSION NO: 0028WE000271 PATIENT ID : VIJEF05058328A CLIENT PATIENT ID: ABHA NO :	AGE/SEX :40 Years Female DRAWN : RECEIVED :13/05/2023 08:55:34 REPORTED :18/05/2023 13:44:08
Test Report Status <u>Preliminary</u>	Results Biological	Reference Interval Units

BASIC EYE EXAMINATION

CONJUNCTIVA	NORMAL
EYELIDS	NORMAL
EYE MOVEMENTS	NORMAL
CORNEA	NORMAL
DISTANT VISION RIGHT EYE WITHOUT GLASSES	NORMAL
DISTANT VISION LEFT EYE WITHOUT GLASSES	NORMAL
NEAR VISION RIGHT EYE WITHOUT GLASSES	NORMAL
NEAR VISION LEFT EYE WITHOUT GLASSES	NORMAL
COLOUR VISION	NORMAL

BASIC ENT EXAMINATION

EXTERNAL EAR CANAL	NORMAL
TYMPANIC MEMBRANE	NORMAL
NOSE	NO ABNORMALITY DETECTED
SINUSES	NORMAL
THROAT	NO ABNORMALITY DETECTED
TONSILS	NOT ENLARGED

SUMMARY

RELEVANT HISTORY RELEVANT GP EXAMINATION FINDINGS RELEVANT LAB INVESTIGATIONS RELEVANT NON PATHOLOGY DIAGNOSTICS REMARKS / RECOMMENDATIONS NOT SIGNIFICANT NOT SIGNIFICANT HIGH ESR, BACTERIURIA NO ABNORMALITIES DETECTED PLEASE CORELATE CLINICALLY

Page 21 Of 23





View Report

View Details



PERFORMED AT : Agilus Diagnostics Ltd (Formerly SRL Ltd) E-368, Lgf, Nirman Vihar,Near Nirman Vihar Metro New Delhi, 110092 New Delhi, India Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956 Email : wellness.eastdelhi@srl.in



PATIENT NAME : VIJETA JAISWAL	REF. DOCTOR :	SELF
ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703. LADO SARAI. MEHRAULISOUTH WEST	ACCESSION NO: 0028WE000271 PATIENT ID : VIJEF05058328A CLIENT PATIENT ID: ABHA NO :	AGE/SEX :40 Years Female DRAWN : RECEIVED :13/05/2023 08:55:34 REPORTED :18/05/2023 13:44:08
Test Report Status Preliminary	Results Biological	Reference Interval Units

Page 22 Of 23





View Details

View Report



PERFORMED AT : PERFORMED A1 : Agilus Diagnostics Ltd (Formerly SRL Ltd) E-368, Lgf, Nirman Vihar,Near Nirman Vihar Metro New Delhi, 110092 New Delhi, India Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956 Email : wollpace acatdebi@crf in Email : wellness.eastdelhi@srl.in

.

.



PATIENT NAME: VIJETA JAISWAL	REF. DOCTOR :	SELF
ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	ACCESSION NO: 0028WE000271 PATIENT ID : VIJEF05058328A CLIENT PATIENT ID: ABHA NO :	AGE/SEX :40 Years Female DRAWN : RECEIVED :13/05/2023 08:55:34 REPORTED :18/05/2023 13:44:08
Test Report Status <u>Preliminary</u>	Results Biological	Reference Interval Units

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

ULTRASOUND ABDOMEN ULTRASOUND ABDOMEN

HEPATOMEGALY WITH FATTY CHANGE LIVER

Interpretation(s)

THIS REPORT CARRIES THE SIGNATURE OF OUR LABORATORY DIRECTOR. THIS IS AN INVIOLABLE FEATURE OF OUR LAB MANAGEMENT SOFTWARE. HOWEVER, ALL EXAMINATIONS AND INVESTIGATIONS HAVE BEEN CONDUCTED BY OUR PANEL OF DOCTORS.

End Of Report

Please visit www.srlworld.com for related Test Information for this accession

CONDITIONS OF LABORATORY TESTING & REPORTING		
CONDITIONS OF LABORATO 1. It is presumed that the test sample belongs to the patient named or identified in the test requisition form. 2. All tests are performed and reported as per the turnaround time stated in the AGILUS Directory of Services. 3. Result delays could occur due to unforeseen circumstances such as non-availability of kits / equipment breakdown / natural calamities / technical downtime or any	 5. AGILUS Diagnostics confirms that all tests have been performed or assayed with highest quality standards, clinical safety & technical integrity. 6. Laboratory results should not be interpreted in isolation; it must be correlated with clinical information and be interpreted by registered medical practitioners only to determine final diagnosis. 	
 attraction callinetes / technical downtime of any other unforeseen event. A requested test might not be performed if: Specimen received is insufficient or inappropriate Specimen quality is unsatisfactory Incorrect specimen type Discrepancy between identification on specimen container label and test requisition form 	 7. Test results may vary based on time of collection, physiological condition of the patient, current medication or nutritional and dietary changes. Please consult your doctor or call us for any clarification. 8. Test results cannot be used for Medico legal purposes. 9. In case of queries please call customer care (91115 91115) within 48 hours of the report. 	
	Agilus Diagnostics Limited Fortis Hospital, Sector 62, Phase VIII,	

Mohali 160062

Page 23 Of 23



View Details



PERFORMED AT : Agilus Diagnostics Ltd (Formerly SRL Ltd) E-368, Lgf, Nirman Vihar,Near Nirman Vihar Metro New Delhi, 110092 New Delhi, India Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956 Email : wellness.eastdelhi@srl.in